In a nutshell This study compared 6-month and 18-month courses of hormonal anti-androgen treatment and radiotherapy (RT) in patients with locally advanced prostate cancer (LAPC). The results showed that 18-month treatment was most effective, especially when used with high dose brachytherapy RT. Some background Androgens (such as testosterone) are...
Read MoreCurrent stage -Stage IV Posts on Medivizor
Quality of life in patients with advanced prostate cancer after apalutamide treatment
In a nutshell This study analyzed the health-related quality of life (HRQOL) in patients with metastatic castration-sensitive prostate cancer (MCSPC) after treatment with apalutamide (Erleada) and androgen deprivation therapy (ADT). The study found that apalutamide plus ADT was well tolerated and improved survival compared to ADT alone in these...
Read MoreEvaluating the order of hormone therapy drugs for patients with prostate cancer
In a nutshell This study evaluated the order of treatment with two different hormone therapy drugs in patients with castration-resistant prostate cancer that has spread. This study found that treatment with abiraterone acetate (Yonsa) then enzalutamide (Xtandi) delayed cancer growth or spread longer than the same drugs in the opposite...
Read MoreAbiraterone acetate and prednisone in patients with metastatic, castration‑sensitive prostate cancer
In a nutshell This study evaluated if the benefit of adding abiraterone acetate (Zytiga) + prednisone (Deltasone) to androgen-deprivation therapy (ADT) in treating metastatic, castration-sensitive prostate cancer (mCSPC) would be maintained in patients treated with ADT alone. This study concluded that this treatment...
Read MoreEvaluating the safety of re-treatment with radium-223
In a nutshell This study aimed to evaluate the safety and effectiveness of radium-223 (Xofigo, formerly known as Alpharadin) in patients with advanced prostate cancer that has spread to the bones and who have had this treatment previously. This study found that re-treatment with radium-223 was well tolerated and with good results. Some background...
Read MoreSearching for patients with advanced prostate cancer to test a new medication
In a nutshell This phase 2b trial will evaluate ModraDoc006 (MOD) in patients with metastatic castration-resistant prostate cancer (mCRPC). The main outcomes will be the objective response rate (ORR). This trial is recruiting at a number of locations in the US. The details Metastatic castration-resistant prostate cancer (mCRPC) is...
Read MoreEvaluating enzalutamide plus androgen deprivation therapy to treat metastatic prostate cancer
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) with androgen deprivation therapy (ADT) in metastatic prostate cancer. This study found that this combination was associated with longer progression-free and overall survival compared to ADT alone. Some background Patients...
Read MoreComparing the effectiveness of various treatments for high-risk prostate cancer
In a nutshell This study compared the effectiveness of current treatment options for high-risk prostate cancer (PCa). It found that RP is the preferred treatment option for these patients. Some background Prostate surgery (RP) is a common treatment option for high-risk PCa. Radiation therapy (RT), androgen deprivation therapy...
Read MoreEvaluating enzalutamide to treat metastatic prostate cancer
In a nutshell This study aimed to examine the effectiveness and safety of enzalutamide (Xtandi) in metastatic prostate cancer. This study found that enzalutamide was associated with longer progression-free and overall survival compared to standard of care. Some background Enzalutamide is an anti-androgen medication....
Read MoreLooking for patients with advanced melanoma to test a new drug
In a nutshell This phase 1 trial will investigate the safety of an experimental drug, XmAb22841 (XmAb), to treat advanced cancer. The main outcome will be the safety and tolerability of XmAb. This study is recruiting in Georgia and Texas, USA. The details Advanced cancer can be difficult to treat. New drugs are being developed to...
Read MoreSearching for patients with metastatic castration resistant prostate cancer to test a targeted therapy option
In a nutshell This phase 2 trial is examining the effectiveness and safety of trametinib (Mekinist) in patients with metastatic castration-resistant prostate cancer (mCRPC; prostate cancer which has spread from its original place to another area in the body and keeps growing even when the amount of testosterone in the body...
Read MoreSearching for patients with prostate cancer to test this new treatment combination
In a nutshell This phase 2 trial is examining the effectiveness and safety of navarixin (MK-7123) in combination with pembrolizumab (Keytruda) in patients with castration-resistant prostate cancer (CRPC; cancer that progresses after hormonal therapy). The main outcome to be measured will be the objective response rate (ORR; tumor shrinkage or...
Read More
